Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biochem Biophys Res Commun ; 479(4): 721-727, 2016 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-27693584

RESUMO

Pompe disease is caused by a deficiency in the lysosomal enzyme α-glucosidase, and this leads to glycogen accumulation in the autolysosomes of patient cells. Glycogen storage material is exocytosed at a basal rate in cultured Pompe cells, with one study showing up to 80% is released under specific culture conditions. Critically, exocytosis induction may reduce glycogen storage in Pompe patients, providing the basis for a therapeutic strategy whereby stored glycogen is redirected to an extracellular location and subsequently degraded by circulating amylases. The focus of the current study was to identify compounds capable of inducing rapid glycogen exocytosis in cultured Pompe cells. Here, calcimycin, lysophosphatidylcholine and α-l-iduronidase each significantly increased glycogen exocytosis compared to vehicle-treated controls. The most effective compound, calcimycin, induced exocytosis through a Ca2+-dependent mechanism, although was unable to release a pool of vesicular glycogen larger than the calcimycin-induced exocytic pore. There was reduced glycogen release from Pompe compared to unaffected cells, primarily due to increased granule size in Pompe cells. Drug induced exocytosis therefore shows promise as a therapeutic approach for Pompe patients but strategies are required to enhance the release of large molecular weight glycogen granules.


Assuntos
Calcimicina/farmacologia , Exocitose/efeitos dos fármacos , Doença de Depósito de Glicogênio Tipo II/metabolismo , Glicogênio/metabolismo , Iduronidase/farmacologia , Lisofosfatidilcolinas/farmacologia , Calcimicina/uso terapêutico , Células Cultivadas , Avaliação Pré-Clínica de Medicamentos , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Doença de Depósito de Glicogênio Tipo II/tratamento farmacológico , Humanos , Iduronidase/uso terapêutico , Lisofosfatidilcolinas/uso terapêutico , Lisossomos/efeitos dos fármacos , Fagossomos/efeitos dos fármacos , Veículos Farmacêuticos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA